参考文献/References:
[1] Fanaroff AA,Hack M,Walsh MC. The NICHD neonatal research network:changes in practice and outcomes during the first 15 years[J]. Semin Perinatol,2003,27(4):281-287.
[2] Pass RH,Hijazi Z,Hsu DT,et al. Multicenter USA Amplatzer patent ductus arteriosus occlusion device trial:initial and one-year results[J]. J Am Coll Cardiol,2004,44(3):513-519.
[3] 中国医师协会心血管内科分会先心病工作委员会. 常见先天性心脏病介入治疗中国专家共识 三、动脉导管未闭的介入治疗[A].介入放射学杂志,2011,20(3):172-176.
[4] Clyman RI,Liebowitz M,Kaempf J,et al. PDA-TOLERATE trial:an exploratory randomized controlled trial of treatment of moderate-to-large patent ductus arteriosus at 1 week of age[J]. J Pediatr,2019,205:41-48.
[5] Sivanandan S,Agarwal R. Pharmacological closure of patent ductus arteriosus:selecting the agent and route of administration[J]. Paediatr Drugs,2016,18(2):123-138.
[6] Herrera C,Holberton J,Davis P. Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants[J]. Cochrane Database Syst Rev,2007,18(2):CD003480.
[7] Irmesi R,Marcialis MA,Anker JV,et al. Non-steroidal anti-inflammatory drugs(NSAIDs) in the management of patent ductus arteriosus(PDA) in preterm infants and variations in attitude in clinical practice:a flight around the world[J]. Curr Med Chem,2014,21(27):3132-3152.
[8] Ohlsson A,Walia R,Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants[J]. Cochrane Database Syst Rev,2020,2(2):CD003481.
[9] Mitra S,Florez ID,Tamayo ME,et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants:a systematic review and meta-analysis[J]. JAMA,2018,319(12):1221-1238.
[10] Demir N,Peker E,Ece I,et al. Efficacy and safety of rectal ibuprofen for patent ductus arteriosus closure in very low birth weight preterm infants[J]. J Matern Fetal Neonatal Med,2017,30(17):2119-2125.
[11] Fowlie PW,Davis PG,McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants[J]. Cochrane Database Syst Rev,2010,(7):CD000174.
[12] Ohlsson A,Shah SS. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants[J]. Cochrane Database Syst Rev,2020,1(1):CD004213.
[13] Yamada S,Terzic A. Path toward proactive therapy for patent ductus arteriosus[J]. Clin Pharmacol Ther,2019,106(6):1187-1190.
[14] Marconi E,Bettiol A,Ambrosio G,et al. Efficacy and safety of pharmacological treatments for patent ductus arteriosus closure:a systematic review and network meta-analysis of clinical trials and observational studies[J]. Pharmacol Res,2019,148:104418.
[15] Mashally S,Nield LE,McNamara PJ,et al. Late oral acetaminophen versus immediate surgical ligation in preterm infants with persistent large patent ductus arteriosus[J]. J Thorac Cardiovasc Surg,2018,156(5):1937-1944.
[16] Ko SM,Yoon YC,Cho KH,et al. Primary surgical closure should be considered in premature neonates with large patent ductus arteriosus[J]. Korean J Thorac Cardiovasc Surg,2013,46(3):178-184.
[17] 陈立波,赵洪序,张秀和,等. 285例粗大动脉导管未闭的外科治疗[J]. 吉林大学学报(医学版),1997,23(1):74-75.
[18] 陈保俊,王淦,魏静义,等. 粗大型动脉导管未闭的外科治疗[J]. 江苏医药,2001,27(3):189-190.
[19] 刘瑞生,邢旺,孙伟,等. 经胸小切口封堵术治疗粗大动脉导管未闭[J]. 中国微创外科杂志,2015,15(9):843-845.
[20] Wen B,Yang J,Liu H,et al. Pulmonary artery closure in combination with patch technique for treating congenital heart disease combined with large patent ductus arteriosus:a clinical study of 9 cases[J]. Pak J Med Sci,2016,32(3):539-544.
[21] Shabbir M,Akhtar K,Maadullah,et al. Transcatheter closure of large sized patent ductus arteriosus using the Amplatzer duct occluder device[J]. J Coll Physicians Surg Pak,2009,19(5):275-278.
[22] Cubeddu RJ,Babin I,Inglessis I. The off-label use of the Amplatzer muscular VSD occluder for large patent ductus arteriosus:a case report and review[J]. Cardiovasc Interv Ther,2014,29(3):256-260.
[23] 尚小珂,黄鹤. 使用肌高5室间隔缺损封堵器封堵婴儿巨大动脉导管未闭的研究[J]. 中国介入心脏病学杂志,2014,22(12):781-784.
[24] Garcia-Montes JA,Camacho-Castro A,Sandoval-Jones JP,et al. Closure of large patent ductus arteriosus using the Amplatzer septal occluder[J]. Cardiol Young,2015,25(3):491-495.
[25] Sudhakar P,Jose J,George OK. Contemporary outcomes of percutaneous closure of patent ductus arteriosus in adolescents and adults[J]. Indian Heart J,2018,70(2):308-315.
[26] 谢育梅,邱庆欢,张智伟,等. 生物陶瓷镀膜封堵器治疗儿童左向右分流型先天性心脏病的中远期随访研究[J]. 中华实用儿科临床杂志,2015,30(11):818-822.
[27] 陈芃螈,周超然,李刚. 第二代Cera动脉导管未闭封堵器介入治疗小儿先天性心脏病的疗效分析[J]. 临床小儿外科杂志,2019,18(7):573-578.
[28] Godart F,Houeijeh A,Domanski O,et al. Is the new Occlutech duct occluder an appropriate device for transcatheter closure of patent ductus arteriosus?[J]. Int J Cardiol,2018,261:54-57.
[29] Pepeta L,Greyling A,Nxele MF,et al. Patent ductus arteriosus closure using Occlutech Duct Occluder, experience in Port Elizabeth, South Africa[J]. Ann Pediatr Cardiol,2017,10(2):131-136.
[30] Dedeoglu R,Bilici M,Demir F,et al. Short-term outcomes of patent ductus arteriosus closure with new Occlutech? duct occluder:a multicenter study[J]. J Interv Cardiol,2016,29(3):325-331.
[31] Kudumula V,Taliotis D,Duke C. The new occlutech duct occluder:immediate results,procedural challenges,and short-term follow-up[J]. J Invasive Cardiol,2015,27(5):250-257.
[32] Boudjemline Y. The new Occlutech(?) patent ductus arteriosus occluder:single centre experience[J]. Arch Cardiovasc Dis, 2016,109(6-7):384-389.
[33] Abdelbasit MA,Alwi M,Kandavello G,et al. The new Occlutech? PDA occluder:initial human experience[J]. Catheter Cardiovasc Interv,2015,86(1):94-99.
[34] Bilici M,Demir F,Ak?n A,et al. Transcatheter closure of patent ductus arteriosus in children with the occlutech duct occluder[J]. Pediatr Cardiol,2017,38(8):1598-1605.
[35] Lehner A,Ulrich S,Happel CM,et al. Closure of very large PDA with pulmonary hypertension:initial clinical case-series with the new Occlutech? PDA occluder[J]. Catheter Cardiovasc Interv,2017,89(4):718-725.
[36] Sinha SK,Razi M,Pandey RN,et al. Prospective evaluation of the feasibility,safety,and efficacy of Cocoon Duct Occluder for transcatheter closure of large patent ductus arteriosus:a single-center study with short- and medium-term follow-up results[J]. Anatol J Cardiol,2017,18(5):321-327.
相似文献/References:
[1]黄淮滨 刘甲兴.肥厚型心肌病治疗新靶点——钙脱敏治疗[J].心血管病学进展,2019,(7):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
HUANG HuaibinLIU Jiaxing.A Novel Target for Therapy in Hypertrophic Cardiomyopathy: Ca2+ desensitizer[J].Advances in Cardiovascular Diseases,2019,(1):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
[2]李可 田进文 邓珏琳.老年高血压的临床诊治研究进展[J].心血管病学进展,2019,(9):1208.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.006]
LI Ke,TIAN Jinwen,DENG Juelin.Diagnosis and Treatment in Elderly Hypertension[J].Advances in Cardiovascular Diseases,2019,(1):1208.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.006]
[3]罗芩 何庆.TNF凝集素样结构域：高原肺水肿药物治疗新选择罗芩 何庆2[J].心血管病学进展,2019,(9):1301.[doi:10.16806/j.cnki.issn.1004-3934.2019.00.030]
LUO QinHE Qing.The Lectin-like Domain of TNF:New Drug Treatment Option for HAPE[J].Advances in Cardiovascular Diseases,2019,(1):1301.[doi:10.16806/j.cnki.issn.1004-3934.2019.00.030]
[4]郭岐龙 芦颜美 张玲 张疆华 邢强 祖克拉·吐尔洪 李耀东 周贤惠 汤宝鹏.新疆地区老年慢性心力衰竭住院患者的病因、合并症及药物治疗的多中心回顾性分析[J].心血管病学进展,2020,(4):414.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.021]
GUO Qilong,LU Yanmei,ZHANG Ling,et al.Etiology, Comorbidity and Drug Treatment of Elderly Inpatients with Chronic Heart Failure in Xinjiang: A Multi-center Retrospective Study[J].Advances in Cardiovascular Diseases,2020,(1):414.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.021]
[5]布热比古力·阿布力米提 付真彦.乳腺癌药物治疗与心肌损伤[J].心血管病学进展,2020,(8):802.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.005]
Burebiguli·abulimitiFU Zhenyan.Drug Therapy of Breast Cancer and Assosiated Myocardial Damage[J].Advances in Cardiovascular Diseases,2020,(1):802.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.005]
[6]王毅 佘强.射血分数降低性心力衰竭的药物进展[J].心血管病学进展,2021,(11):990.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
WANG Yi,SHE Qiang.Advancement of Drug Therapy in Heart Failure with Reduced Ejection Fraction[J].Advances in Cardiovascular Diseases,2021,(1):990.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
[7]于筱斋?高艳香?郭紫玉?陈西霞?叶子翔?郑金刚.非阻塞性冠状动脉疾病的冠状动脉微循环功能障碍治疗新进展[J].心血管病学进展,2022,(5):385.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.001]
YU Xiaozhai,GAO Yanxiang,GUO Ziyu,et al.Treatment of Coronary Microvascular Dysfunction in Non-Obstructive Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2022,(1):385.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.001]
[8]毕淑利 姚朱华.作用于环磷酸鸟苷的抗心力衰竭药物作用机制及研究进展[J].心血管病学进展,2022,(8):735.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.017]
BI Shuli,YAO Zhuhua?/html>.Mechanisms and Research Progress of Anti-Heart Failure Drug?argeting Cyclic Guanosine Monophosphate[J].Advances in Cardiovascular Diseases,2022,(1):735.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.017]
[9]李胜男 谢亮 童嘉毅.阻塞性睡眠呼吸暂停的药物治疗研究进展[J].心血管病学进展,2023,(8):748.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.017]
LI Shengnan,XIE Liang,TONG Jiayi.Advancement of Drug Therapy in Obstructive Sleep Apnea Syndrome[J].Advances in Cardiovascular Diseases,2023,(1):748.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.017]
[10]高鑫 王仲朝.射血分数保留的心力衰竭的药物治疗新进展[J].心血管病学进展,2023,(10):883.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.005]
GAO Xin,WANG Zhongchao.New Progress in Drug Treatment of Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2023,(1):883.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.005]